Kornimate/medical-research-clean huggingface dataset:
effects of mirror therapy and bilateral arm training on hemiparetic upper extremity in patients with chronic stroke

Conditions: Stroke; Hemiplegia

Summary: the aim of this study included (1) to compare the effectiveness of mirror therapy (mt) and bimanual arm training (bat) in improving motor and functional performance of hemiplegic upper extremity for adults with chronic stroke; (2) to examine whether recruitment of the mirror neurons, as reflected in mu rhythm suppression, mediates recognition of the mirror illusion in pre/post mt, as compared to bat without a mirror in clients with chronic stroke, as compared to healthy participants.

mirror therapy (mt) appeared to have beneficial effects on the recovery of distal function of the hemiplegic hand in the evidence recently, however, it is not known whether the incongruent visual feedback induced by mirror in bilateral arm training (bat) is beneficial to the motor performance of upper extremity than without the mirror in patients with chronic stroke. this study aimed to compare the effectiveness of mt and bimanual arm training (bat) in improving motor and functional performance of hemiplegic upper extremity for adults with chronic stroke. participants with chronic stroke were recruited by convenience sampling from a convalescent hospital and self-help groups in the community in hong kong. participants were randomly assigned to the mt group or bat group and participated in a 6-week upper limb training programme which consisted of two 45-minute training sessions per week. both kinds of training were equivalent to each other except that there was a mirror used in the mt group. main outcome measures were upper extremity motor and functional tests, and grip strength. participants were evaluated at baseline, post-treatment and 3-month follow-up. eeg was assessed before and after the training in a group of stroke patients and healthy controls, in order to evaluate the recruitment of the mirror neurons, as reflected in mu rhythm suppression.

Eligibility criteria:
inclusion criteria: 1. neurological condition with unilateral hemiparesis; 2. a functional test of hemiplegic upper extremity (fthue) score between levels 2 to 6; 3. chronic stroke with onset of neurological condition more than 6 months previously; 4. ability to understand and follow simple verbal instructions; 5. ability to participate in a therapy session lasting at least 30 minutes; 6. community ambulant with or without aids. exclusion criteria: individuals with severe neglect and severe spasticity (modified ashworth scale \>3) would be excluded.

Keywords: stroke mirror therapy bilateral arm training upper limb function
post-market, long-term follow up of mobi-c® cervical disc for one and two level treatment of cervical disc disease

Conditions: Cervical Disc Disease; Cervical Disc Degeneration

Summary: the purpose of this study is to evaluate clinical and patient-reported outcomes at 10 years following surgery for a cohort of mobi-c subjects treated on the ide/post approval studies

this is a prospective, multi-center, consecutive cohort study. subjects invited to participate in this study will have completed the mobi-c ide study (g050212). in this study, five hundred and seventy-five subjects were randomized to either the mobi-c prosthesis or the control treatment - conventional anterior cervical discectomy and fusion (acdf) with anterior cervical plating. the study was randomized in a 2 to 1 ratio (two mobi-c subjects for every one subject receiving acdf with anterior cervical plate). the subject retention rate for mobi-c subjects was 80.1% (1 level)-84.4% (2 level) at 7 years. as non-inferiority (1-level) and superiority (2-level) have been well established through 7 years, the design of this study will focus on the long-term outcomes of a cohort of the mobi-c arm of the study and evaluate the durability of outcomes at 10 years. study sites invited to participate will be those that enrolled at least 10 subjects, and also had the highest retention rates at 7 years (≥70%). all subjects at these sites will be contacted to participate in an additional 10 year follow up visit. it is estimated that up to 250 subjects will be enrolled at 9-12 study sites. certain endpoints are better assessed in comparison to the control acdf arm, such as adjacent segment degeneration and subsequent surgery. this study has been amended to include a subset of sites that will also enroll control subjects. up to 3 sites and 50 subjects will be included in this control cohort.

Eligibility criteria:
inclusion criteria: 1. prior enrollment in ldr-001 pivotal study (ide g050212); 2. written informed consent provided by subject or subject's legally authorized representative exclusion criteria: 1. documented withdrawal of consent from prior mobi-c study; 2. documented non-compliance (including unwillingness to return to the site for follow-up visits) 3. reported pregnancy at time of enrollment, or with plans to become pregnant prior to completing study x-rays
acute effects of exercise in women with fibromyalgia (fm)

Conditions: Fibromyalgia

Summary: the investigators previous studies of aerobic exercise in women with fibromyalgia (fm) have shown that exercise improves body functions and/or symptom severity in most patients, but not in all. about a third of patients with fm have been shown to have low levels of igf-1. the purpose of this project is to study individual and biological factors that interact with outcomes of short-term (acute) exercise in fm. method. a controlled prospective exercise study. thirty women with fm and 30 healthy age-matched women, aged 20-50 years, will be recruited to the study. two 15-minute ergometer bicycle exercise tests will be conducted in feasting patients, separated by one month. the first exercise test is at a low and the second at a high intensity. measurements comprise blood test, pain rating and pain threshold, conducted before and after the test. the levels of igf-1, il-6 and il-8 will be measured, and the changes in them will be related to health status and pain.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of fibromyalgia * age 20-50 years exclusion criteria: * heart disease * neurological disease * severe osteoarthritis

Keywords: fibromyalgia pain women exercise igf1
to evaluate the safety and tolerability of combined administration of shr2285 tablets with aspirin, clopidogrel or ticagrelor in healthy subjects

Conditions: Thrombosis

Summary: the study is a single-center，randomized, doubled-blinded, placebo-controlled, only for shr2285 phase i trial. this study intends to enroll 52 healthy subjects, regardless of gender. the subjects are divided into three groups: a, b, and c, with 16 cases in each of groups a and b, and 20 cases in group c.


Eligibility criteria:
inclusion criteria: 1. healthy subjects, aged 18-55 (including boundary); 2. body mass index (bmi) between 19 to 28 kg/m2 (including boundary), male body weight ≥50 kg and \<90 kg , female body weight ≥45kg and \<90kg; 3. participant with no clinically significant findings in vital signs, physical examination, 12-lead ecg ,x-ray and laboratory parameters，etc. 4. understand the study procedures and methods, voluntary to participate in the study and signed the informed consent. exclusion criteria: 1. alanine aminotransferase (alt) or aspartate aminotransferase (ast) or total bilirubin/direct bilirubin \> 1.2 fold uln during screening/baseline. 2. serum creatinine\> uln during screening/baseline. 3. positive faecal occult blood 4. abnormal coagulation function. 5. a clinical history of coagulation dysfunction; subjects with adverse reaction of antiplatelet drugs or anticoagulant drugs. 6. subjects with severe head trauma or head surgery within 2 years or surgery within 3 months prior to the screening. 7. blood donation or blood loss within 1 month≥200 mlor≥400 ml within 3 months before administration. 8. human immunodeficiency virus antibody, syphilis serological examination, hepatitis b virus surface antigen, hepatitis c virus antibody were positive. 9. 3 months prior to screening involved in any drug or medical device clinical studies. . 10. female subjects who did not receive contraception at least 30 days before administration and etc.
effects of online cognitive control training on rumination and depressive symptoms

Conditions: Depression; Rumination - Thoughts

Summary: the present study examines whether a computerized cognitive control training as compared to a placebo (fake) training will reduce the frequency of depressive rumination in depressed individuals. rumination has been identified as a major risk factor for the onset and recurrence of depressive episodes and it has been suggested that it is linked to deficits in cognitive control functions. it is thus expected that training cognitive control will reduce the frequency of rumination as well as ameliorate its detrimental effect on negative mood states.

rumination has been shown to intensify dysphoric mood and is one of the best researched risk factors for the onset and recurrence of depressive episodes. accumulating evidence suggests that the tendency to ruminate is linked to impairments in cognitive control functions, especially to problems discarding no longer relevant negative material from working memory (=working memory updating). the aim of the present study is to examine whether training to update emotional material in working memory will have an effect on the frequency of using rumination as well as on the impact of rumination on mood in the daily lives of clinically depressed participants. participants will be randomly assigned to 10 sessions of either online cognitive control training or an online placebo condition. the ability to update emotional material in working memory will be assessed pre and post training by two computer tasks (close and far transfer tasks). the effects of the training on daily rumination and the dynamics between daily mood and rumination will be assessed pre- and post-training, as well as at 3-months follow-up using ambulatory assessment (via smartphone app). it is expected that individuals in the training as compared to the placebo group will show a greater reduction in rumination frequency as well as a reduction in the negative impact of rumination on mood.

Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorders 5th edition (dsm-5) criteria for a current major depressive episode * 18-65 years of age * german native language (due to verbal task requirements) exclusion criteria: * life time diagnosis of any bipolar or psychotic disorder, or substance dependence * substance use disorder within past 12 months * current obsessive-compulsive disorder (ocd) or borderline personality disorder (bps) * reporting severe underweight (bmi\<18), any neurological disease, severe head injury (e.g. severe concussion), or any brain damage (e.g. due to stroke) * concurrent psychotherapy during the duration of the study
ultrasound-guided hydrodilatation with triamcinolone acetonide for adhesive capsulitis

Conditions: Postoperation Pain

Summary: the purpose of this study was to compare the efficacy of ultrasus-guided hydrodilation of rotator cuff interval combined with posterior glenohumeral recess approach and hydrodilation of the rotator cuff interval alone in adhesive capsulitis.

for patients with perihumeral arthritis, shoulder capsule hydrodilation is usually performed using ultrasound-guided water dilation through the posterior glenohumeral recess. recently, a new transrotator cuff space approach has been described, and this study was designed to compare the efficacy of triamcinolone olonide transrotator cuff space combined with posterior glenohumeral recess and rotator cuff space dilation in the treatment of adhesive joint capsitis.

Eligibility criteria:
inclusion criteria: 1. age ≥18 years old, clinical diagnosis of periarthritis of shoulder; 2. symptom duration \> 1 month, shoulder rom limitation in at least two directions, defined as abduction \< 80°, flexion \< 130°, and rotation \< 30°; 3. before enrollment, the patients received plain radiographs, ultrasound images, and magnetic resonance imaging to rule out the cause of secondary shoulder capsitis. exclusion criteria: 1. secondary frozen shoulder, such as rotator cuff tear, calcifying tendinitis, osteoarthritis, infection, tuberculosis infection, rheumatic disease, shoulder impingement syndrome; 2. previous history of shoulder joint surgery; 3. involved cervical nervous system symptoms or abnormal nervous system; 4. corticosteroid injection in the affected shoulder within 3 months; 5. mental illness; 6. patients with contraindications to cortisol-hormone use.

Keywords: adhesive capsulitis hydrodilatation corticosteroid rotator cuff interval posterior glenohumeral recess
safety, efficacy, and tolerability of nbi-827104 for the treatment of essential tremor

Conditions: Essential Tremor

Summary: the main objective of this study is to evaluate the efficacy, safety, and tolerability of nbi-827104 in adults with essential tremor.


Eligibility criteria:
inclusion criteria: 1. male or female subjects, 18 to 75 years of age, inclusive at screening. 2. body mass index (bmi) between 18 and 35 kg/m², inclusive, at screening. 3. diagnosis of essential tremor (inclusive of essential tremor plus) as defined by the movement disorders society consensus criteria for tremor. 4. confirmation of bilateral upper limb action tremor in the absence of overt dystonia, ataxia, or parkinsonism. 5. history of onset of tremor before 65 years of age. 6. tremor performance score of ≥ 2 on at least 2 of the 6 upper limb manoeuvres (item 4) on the tetras performance subscale and a total tetras performance score ≥15 at screening. 7. all women of childbearing potential and all males must practice effective contraception during the study and be willing and able to continue contraception for at least 90 days after their last dose of study drug. exclusion criteria: 1. evidence of any acute (at screening or prior to first dose) or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator. 2. have direct or indirect trauma to the nervous system within 3 months preceding the onset of tremor. 3. have known history of other medical or neurological conditions that may cause or explain subject's tremor. 4. have had prior magnetic resonance guided focused ultrasound or surgical intervention (e.g., deep brain stimulation, ablative thalamotomy or gamma knife thalamotomy). 5. have a history or evidence of clinically significant cardiac conduction abnormality, uncontrolled bradyarrhythmia, heart failure, or long qt syndrome.

Keywords: movement disorder tremor syndrome
development and evaluation of the dea app

Conditions: Dementia

Summary: background, current situation, and motivation according to current estimates, 100,000 people in austria suffer from various types of dementia. according to forecasts, this number of people will rise to approximately 230,000 by 2050 due to the demographic development and the increase of the prevalence rate. data from the service statistics show that 85% of dementia patients still live in the community in their homes and informal caregivers, such as relatives, support them. in total, more than 300,000 people care for their relatives in austria in addition to professional support. however, not only the person affected from dementia suffers from the disease, but also, and often at a higher rate, the informal caregivers. vice versa, the quality of life of those suffering from dementia is significantly influenced by the caregivers' competences and their strategies for resilience. study aim and hypothesis the aim of this study is to evaluate the usability, acceptance, and effect of an app consisting of three modules that provide multidimensional support for informal caregivers of a person with dementia.


Eligibility criteria:
inclusion criteria: * informal caregivers of a person with dementia * 18 years or older * enough language skills to participate * give written and oral informed consent * have an android smartphone or tablet (required to use the app). exclusion criteria: * none

Keywords: informal caregivers person with dementia e-health solution
evaluation of regional myocardial dynamics at physical stress in essential hypertension

Conditions: Hypertension; Left Ventricular Hypertrophy

Summary: the study hypothesis is stress-related regional tissue dynamics is related to left ventricular outflow tract blood flow.


Eligibility criteria:
inclusion criteria: * essential hypertension exclusion criteria: * history of myocardial infarction * diabetes mellitus * renal failure * orthopedic problems
comparison of the effectiveness of first-line preventive treatment of migraine in primary care

Conditions: Migraine

Summary: this study, which is aimed at comparing the effectiveness of the most frequently used drugs in the first line in primary care for the preventive treatment of migraine (amitriptyline, flunarizine, topiramate and propranolol), is a multicentre, pragmatic, parallel group, open randomised trial. adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial, will be randomised to one of the 4 groups. sample: 460 patients. the primary outcome will be the reduction in monthly migraine days, comparing amitriptyline, flunarizine and topiramate with propranolol.


Eligibility criteria:
inclusion criteria: - adults (≥18) candidates for preventive treatment for migraine; those with a frequency of ≥4 monthly migraine days, and who agree to participate in the clinical trial. exclusion criteria: * people diagnosed with migraine who are not candidates for preventive migraine treatment * people diagnosed with chronic migraine (\>15 days of headache per month, of which 8 are monthly migraine days) * not having a smartphone * simultaneous participation in another clinical trial * pregnancy or expected pregnancy during the next 3 months * lactation * people with migraine who already receive preventive treatment. * people on chronic treatment with opioids or other analgesics or nsaids that are not used for the symptomatic treatment of migraine, for example, osteoarthritis. * people who, in the opinion of the clinician, have an absolute contraindication to one of the study drugs or who cannot perform the trial procedures: hypersensitivity to any of the study drugs / heart block or severe bradycardia / concomitant treatment with verapamil or diltiazem / active cardiovascular pathology (recent heart attack, angina, raynaud's phenomenon) / major depression or active treatment with antidepressants (including monoamine oxidase inhibitors and st. john's wort) / other psychiatric illnesses or active treatment with antipsychotics or lithium / severe liver disease or kidney failure / parkinson's disease or other extrapyramidal disorders / epilepsy (diagnosis and/or active treatment) / any other contraindication that, in the opinion of the clinician, prevents participation in the clinical trial

Keywords: migraine monthly migraine days (mmd) preventive treatment primary care
a diagnostic test to evaluate cancer risk before surgery in women with an ovarian mass

Conditions: Ovarian Neoplasms

Summary: ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. cleo diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. in initial studies, this test outperformed the current standard test, ca125, in identifying cancer. this study aims to evaluate the effectiveness of the cleo diagnostics (cleodx) ovarian adnexal mass score test system. this test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. the test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. by doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.


Eligibility criteria:
inclusion criteria: * female patients =\> 18 years of age at the time of consent * can provide written informed consent * have an ovarian cyst or adnexal mass (simple, complex, or solid ovarian/pelvic mass) identified through imaging examination (e.g. transvaginal ultrasound - tvu) that requires surgery, but have not yet undergone this surgery exclusion criteria: * any prior confirmed diagnosis of, or treatment for, ovarian cancer * any prior surgery resulting in removal of both ovaries * prior history of gynecological malignancy (within last 2 years) * prior history of melanoma (within last 2 years) * prior treatment (within 12 months of sample collection) with chemotherapy, radiotherapy or immunotherapy * immune-compromised. definition: those whose weakened immune system may render them more susceptible to infection, illness, or complications. these may include patients with immune-suppressive conditions (e.g. hiv/aids), patients undergoing immuno-, chemo- or radio-therapy (within the last 12 months) for any reason, receiving immune suppressive therapies (e.g. transplant recipients, individuals with known autoimmune disease), or with a primary immunodeficiency disorder (e.g. lupus). * pregnant currently or within the last 3 months based on participant self-report

Keywords: ovarian adnexal benign malignant cancer
phase i single ascending dose/multiple ascending dose in patients treated with azd7762 and irinotecan

Conditions: Advanced Solid Tumors; Cancer; Advanced Solid Malignancies

Summary: this is an open-label, multi-center, dose-escalation and safety expansion, phase i study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of azd7762 administered as a single intravenous unit and in combination with irinotecan. the study is sponsored by astrazeneca.


Eligibility criteria:
inclusion criteria: * advanced solid tumors for which standard treatment doesn't exist or is no longer effective. * must be suitable for treatment with irinotecan * relatively good overall health other than your cancer exclusion criteria: * poor bone marrow function (not producing enough blood cells) * serious heart conditions * poor liver or kidney function * any prior anthracycline treatment

Keywords: phase i solid tumors solid malignancies cancer eligibility